Efficacy of the nicotine vaccine 3'-AmNic-rEPA (NicVAX) co-administered with varenicline and counselling for smoking cessation: A randomized placebo-controlled trial

Addiction

Volumn 109, Issue 8, 2014, Pages 1252-1259

  Hoogsteder, Philippe H J ^a   Kotz, Daniel ^a   van Spiegel, Paul I ^b   Viechtbauer, Wolfgang ^a   van Schayck, Onno C P ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Efficacy; Immunogenicity; Nicotine vaccine; Placebo; Randomized; Safety; Trial

Indexed keywords

BENZAZEPINE DERIVATIVE; NICOTINE VACCINE; NICOTINIC AGENT; QUINOXALINE DERIVATIVE; VACCINE; VARENICLINE;

ADOLESCENT; ADULT; AGED; CONTROLLED STUDY; COUNSELING; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG THERAPY; FEMALE; HUMAN; MALE; MIDDLE AGED; NETHERLANDS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SMOKING; SMOKING CESSATION; STATISTICS AND NUMERICAL DATA; THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BENZAZEPINES; COUNSELING; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; NICOTINIC AGONISTS; QUINOXALINES; RECURRENCE; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; VACCINES; YOUNG ADULT;

EID: 84903999150     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12573     Document Type: Article

References (22)

1. World Health Organization. WHO report on the global tobacco epidemic 2011: warning about the dangers of tobacco. World Health Organization, 2011. Available at: http://whqlibdoc.who.int/publications/2011/9789240687813_eng.pdf (accessed 5 February 2013) (Archived at http://www.webcitation.org/5Kt3PxfFl on 30 April 2014).
2. Thun M. J., Carter B. D., Feskanich D., Freedman N. D., Prentice R., Lopez A. D. etal. 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013; 368: 351-364.
3. Jha P., Ramasundarahettige C., Landsman V., Rostron B., Thun M., Anderson R. N. etal. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013; 368: 341-350.
4. Stead L. F., Perera R., Bullen C., Mant D., Hartmann-Boyce J., Cahill K. etal. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012; (11): CD000146.
5. Hughes J. R., Stead L. F., Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; (1): CD000031.
6. Cahill K., Stead L. F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; 4: CD006103.
7. West R., Zatonski W., Cedzynska M., Lewandowska D., Pazik J., Aveyard P. etal. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011; 365: 1193-1200.
8. Stead L. F., Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev 2012; (12): CD009670.
9. Cerny E. H., Cerny T. Vaccines against nicotine. Hum Vaccin 2009; 5: 200-205.
10. Pentel P., Malin D. A vaccine for nicotine dependence: targeting the drug rather than the brain. Respiration 2002; 69: 193-197.
11. Hartmann-Boyce J., Cahill K., Hatsukami D., Cornuz J. Nicotine vaccines for smoking cessation. Cochrane Database Syst Rev 2012; 8: CD007072.
12. Hoogsteder P. H., Kotz D., van Spiegel P. I., Viechtbauer W., Brauer R., Kessler P. D. etal. The efficacy and safety of a nicotine conjugate vaccine (NicVAX(R)) or placebo co-administered with varenicline (Champix(R)) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial. BMC Public Health 2012; 12: 1052.
13. Hatsukami D. K., Jorenby D. E., Gonzales D., Rigotti N. A., Glover E. D., Oncken C. A. etal. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 2011; 89: 392-399.
14. Lai D. T., Cahill K., Qin Y., Tang J. L. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev 2010; (3): CD006936.
15. Voller A. The enzyme-linked immunosorbent assay (ELISA) (theory, technique and applications). Ric Clin Lab 1978; 8: 289-298.
16. Bousquet C., Lagier G., Lillo-Le Louet A., Le Beller C., Venot A., Jaulent M. C. Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions. Drug Saf 2005; 28: 19-34.
17. Cappelleri J. C., Bushmakin A. G., Baker C. L., Merikle E., Olufade A. O., Gilbert D. G. Revealing the multidimensional framework of the Minnesota nicotine withdrawal scale. Curr Med Res Opin 2005; 21: 749-760.
18. Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerstrom K. O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86: 1119-1127.
19. Jorenby D. E., Hays J. T., Rigotti N. A., Azoulay S., Watsky E. J., Williams K. E. etal. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56-63.
20. Gonzales D., Rennard S. I., Nides M., Oncken C., Azoulay S., Billing C. B. etal. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47-55.
21. Raupach T., Hoogsteder P. H., Onno van Schayck C. P. Nicotine vaccines to assist with smoking cessation: current status of research. Drugs 2012; 72: e1-16.
22. Hughes J. R., Keely J., Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004; 99: 29-38.